Abstract: Objective To analyze the changes in the use of Chinese patent medicines for cardiovascular diseases at Beijing Huimin Hospital two years after the implementation of the volume-based procurement(VBP) policy, and to evaluate its impact on the clinical medication structure and drug costs. Methods This retrospective study utilized procurement and utilization data of Chinese patent medicines for cardiovascular diseases in Beijing Huimin Hospital from April 1, 2023, to March 31, 2025. The changes in defined daily dose(DDD), daily drug cost(DDC), and total expenditure of different Chinese patent medicines were compared to analyze the intervention effect of the VBP policy. Results Two years after the implementation of VBP, the DDD of most Chinese patent medicines decreased, while that of a few oral medications(such as Xinkeshu preparations and Fufang Xueshuantong preparations) increased. The DDC of the vast majority of drugs decreased, with Guanxinning Injection and Ginkgo Leaf Extract and Dipyridamole Injection exhibiting the largest reduction(both by 20.00%). The actual expenditure on all drugs generally declined, with Dengzhan Shengmai Capsules and Compound Danshen Dripping Pills achieving the most significant cost savings, at RMB 753 100 and RMB 810 700, respectively. Conclusion The VBP policy has effectively promoted the structural adjustment and cost control of Chinese patent medicine use, significantly enhancing the economy and rationality of drug utilization.